Patent US4997748A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4997748A Expired / Lapsed US ⏱️ 0.0 years remaining

Developer solution for positive-working resist composition

Assignee: Tokyo Ohka Kogyo Co Ltd
•
Filing: 1989-08-16
•
Granted: 1991-03-05
•
Expires: 2009-08-16
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The developer solution of the invention is suitable for use to develop a positive-working resist composition comprising an alkali-soluble novolac resin and a naphthoquinone diazide compound and capable of giving a patterned image of the resist layer with a high contrast and increasing the effective depth of focus. The characteristic ingredient in the inventive developer solution is an alkali-soluble organic cyclic nitrogen compound such as N-hydroxyethyl piperazine, N-methyl-4-piperidone, 1,3-dimethyl-2-imidazolidinone and the like added in a specified concentration to a conventional developer solution containing tetramethyl ammonium hydroxide or choline as the water-soluble alkaline compound.

Inventors

  • 👤 Yasuyuki Takeda
  • 👤 Hatsuyuki Tanaka
  • 👤 Toshimasa Nakayama

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-24 07:56
CPC Classifications
G; G03; G03F; G03F7/00; G03F7/26; G03F7/30; G03F7/32; G03F7/322

Claims Analysis

Total Claims: 5
Claim 1
Independent Claim 105 words
A developer solution for developing a positive-working resist composition comprising an alkali-soluble novolac resin and a naphthoquinone diazide compound, which solution comprises: (a) water as the solvent; (b) a water-soluble organic alkaline compound dissolved in the solvent in a concentration in the range from 1.0 to 10.0% by weight; and (c) an alkali-soluble organic cyclic nitrogen compound dissolved in the solvent in a concentration in the range from 0.1 to 10% by weight, wherein said compound is selected from the group consisting essentially of 2-hydroxyethyl pyridine, N-methyl piperazine, N-hydroxyethyl piperazine, 2-hydroxyethyl piperazine, N-hydroxyethyl piperazine, 2-methyl imidazole, 4-(2-hydroxyethyl) morpholine, 1-(2-hydroxyethyl) pyrrolidone, N-methyl-4-piperidone and 2-amino thiazole, 1,3-dimethyl-2-imidazolidinone.
Claim 2
Dependent Claim 105 words
A developer solution for developing a positive-working resist composition comprising an alkali-soluble novolac resin and a naphthoquinone diazide compound, which solution comprises: (a) water as the solvent; (b) a water-soluble organic alkaline compound dissolved in the solvent in a concentration in the range from 1.0 to 10.0% by weight; and (c) an alkali-soluble organic cyclic nitrogen compound dissolved in the solvent in a concentration in the range from 0.1 to 10% by weight, wherein said compound is selected from the group consisting essentially of 2-hydroxyethyl pyridine, N-methyl piperazine, N-hydroxyethyl piperazine, 2-hydroxyethyl piperazine, N-hydroxyethyl piperazine, 2-methyl imidazole, 4-(2-hydroxyethyl) morpholine, 1-(2-hydroxyethyl) pyrrolidone, N-methyl-4-piperidone and 2-amino thiazole, 1,3-dimethyl-2-imidazolidinone.
Claim 3
Dependent Claim 24 words
The developer solution as claimed in claim 1 wherein the water-soluble organic alkaline compound as the component (b) is tetramethyl ammonium hydroxide or choline.
Claim 4
Dependent Claim 31 words
The developer solution as claimed in claim 1 wherein the alkali-soluble organic cyclic nitrogen compound as the component (c) is selected from the group consisting of N-hydroxyethyl piperazine, N-methyl-4-piperidone and 1,3-dimethyl-2-imidazolidinone.
Claim 5
Dependent Claim 21 words
The developer solution as claimed in claim 3 wherein the alkali-soluble organic cyclic nitrogen compound as the component (c) is 1,3-dimethyl-2-imidazolidinone.

References Cited (Backward Citations)

EP0124297A2 Cited
EP0177905A2 Cited
US4729941A Cited
EP0186184A2 Cited
US4744834A Cited
US4820621A Cited
US4820621B1 Cited
EP0286272A2 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1994-03-04 1994-09-03 1995-03-05 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1998-03-04 1998-09-03 1999-03-05 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2002-03-04 2002-09-03 2003-03-05 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag